Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that the U.S. Food and Drug Administration (FDA) has
SAN MATEO, CA. – June 08, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical da
SAN MATEO, CA. – May 12, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced that preclinical data for KT502, its second t